Compounded media powder formulation and method of preparation of liquid medium for cell culture

US10227559B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10227559-B2
Application numberUS-201515302488-A
CountryUS
Kind codeB2
Filing dateApr 7, 2015
Priority dateApr 10, 2014
Publication dateMar 12, 2019
Grant dateMar 12, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides a compounded cell culture medium powder formulation comprising: a basal medium powder and a cell culture media supplement, wherein the cell culture media supplement comprises and one or more salts; one or more growth factors; one or more inorganic ions; an amino acid supplement comprising one or more of asparagine, glutamine, histidine, and serine; one or more buffers; and one or more anti-foaming agents. The invention further provides methods of making a compounded cell culture medium powder formulation methods of making a cell culture medium for growing mammalian cells and methods of producing a protein of interest by culturing cells in the cell culture medium and isolating the protein of interest.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of making a compounded cell culture medium powder formulation for growing mammalian cells, comprising: combining a basal medium powder having the following components at the following concentrations upon hydration: i) 0.0003-0.003 g/L biotin; ii) 0.035-0.33 g/L calcium chloride; iii) 0.003-0.03 g/L choline chloride; iv) 0.0002-0.002 g/L cyanocobalamin (B 12); v) 1-10 g/L D-mannose; vi) 0.001-0.01 g/L D-calcium pantothenate; vii) 0.3-3.0 g/L dextrose (anhydrous); viii) 0.00003-0.0003 g/L DL-alpha-lipoic acid; ix) 0.00001-0.00015 g/L ferric nitrate; x) 0.00005-0.0015 g/L ferrous sulfate; xi) 0.001-0.01 g/L folic acid; xii) 0.007-0.20 g/L glycine; xiii) 0.001-0.01 g/L hypoxanthine 2Na; xiv) 0.005-0.05 g/LI-inositol; xv) 0.003-0.03 g/L L-alanine; xvi) 0.08-1.4 /L L-arginine; xvii) 0.006-0.16 g/L L-asparagine; xviii) 0.005-0.10 g/L L-aspartic acid; xix) 0.005-0.05 g/L L-cysteine HCl; xx) 0.02-0.2 g/L L-cystine 2HCl; xxi) 0.005-0.15 g/L L-glutamic acid (anhydrous); xxii) 0.02-1.5 g/L L-glutamine; xxiii) 0.0003-0.003 g/L L-glutathione; xxiv) 0.02-0.2 g/L L-histidine HCl; xxv) 0.03-0.9 g/L L-isoleucine; xxvi) 0.03-0.9 g/L L-leucine; xxvii) 0.05-1.5 g/L L-lysine; xxviii) 0.01-0.3 g/L L-methionine; xxix) 0.02-0.6 g/L L-phenylalanine; xxx) 0.008-0.25 g/L L-proline; xxxi) 0.009-0.25 g/L L-serine; xxxii) 0.03-0.9 g/L L-threonine; xxxiii) 0.006-0.16 g/L L-tryptophan; xxxiv) 0.02-0.9 g/L L-tyrosine 2Na; xxxv) 0.03-0.9 g/L L-valine; xxxvi) 0.01-0.18 g/L magnesium chloride; xxxvii) 0.02-0.12 g/L magnesium sulfate anhydrous; xxxviii) 0.001-0.01 g/L niacinamide; xxxix) 0.0005-0.005 g/L O-phoshphoryl-ethanolamine; xl) 0.1-1.0 g/L potassium chloride; xli) 0.00002-0.0002 g/L putrescine 2HCl; xlii) 0.001-0.01 g/L pyridoxal HCl; xliii) 0.00001-0.0001 g/L pyridoxine HCl; xliv) 0.0001-0.001 g/L riboflavin; xlv) 2.0-15 g/L sodium chloride; xlvi) 0.01-0.2 g/L sodium phosphate monobasic; xlvii) 0.02-0.2 g/L sodium phosphate dibasic anhydrous; xlviii) 0.015-0.15 g/L sodium pyruvate; xlix) 0.001-0.01 g/L thiamine HCl; l) 0.0001-0.001 g/L thymidine; li) 0.00006-0.0015 g/L zinc sulfate; lii) 0.0000003-0.000006 g/L cupric sulfate; liii) 0.0000005-0.000008 g/L selenium dioxide; liv) 0.00001-0.0001 g/L linoleic acid; lv) 0.0001-0.001 g/L beta-mercaptoethanol; lvi) 0.0003-0.005 g/L ethanolamine; with basal media supplement powder having the following components at the following concentrations upon hydration: a) 0.5-5 g/L magnesium chloride; b) 0.5-15 mg/mL insulin; c) one or more additional trace metals selected from the group consisting of: 0.0005-0.01 mg/L ammonium molybdate tetrahydrate, 0.0001-0.01 mg/L chromium potassium sulfate dodecahydrate, 0.001-0.125 mg/L cupric sulfate pentahydrate, 0.001-0.1 mg/L of litium chloride (anhydrous) 0.00004-0.004 mg/L manganese sulfate hydrate, and 0.04-4.2 mg/L of sodium metasilicate nonahydrate; d) one or more additional amino acid selected from the group consisting of 0.007-0.07 g/L asparagine hydrate, 0.25-2.5 g/L glutamine, 0.5-5 g/L histidine free base, and 0.01-0.1 g/L serine; e) one or more buffers; and f) one or more anti-foaming agents, to make a cell culture medium powder, wherein the cell culture media when hydrated completely dissolves the media components.

Assignees

Inventors

Classifications

  • Organic phosphate, e.g. beta glycerophosphate · CPC title

  • C12N5/0018Primary

    Culture media for cell or tissue culture (media for specific animal cell type C12N5/06) · CPC title

  • Amino acids · CPC title

  • Sugars · CPC title

  • Thiols, e.g. mercaptoethanol · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10227559B2 cover?
The present invention provides a compounded cell culture medium powder formulation comprising: a basal medium powder and a cell culture media supplement, wherein the cell culture media supplement comprises and one or more salts; one or more growth factors; one or more inorganic ions; an amino acid supplement comprising one or more of asparagine, glutamine, histidine, and serine; one or more buf…
Who is the assignee on this patent?
Bayer Healthcare Llc
What technology area does this patent fall under?
Primary CPC classification C12N5/0018. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).